This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Reckitt Benckiser Prepares for Pharma Unit Spinoff

LONDON (The Deal) -- British consumer healthcare and cleaning products company Reckitt Benckiser said on Monday it has decided to spin off its pharmaceuticals unit on the London Stock Exchange within the next 12 months after the division's core Suboxone heroin-withdrawal aid lost U.S. patent protection.

 

Reckitt, of Slough, England, made the announcement as it released first-half results that showed that pharmaceuticals sales fell 14% to 344 million pounds, while the division's operating profit slipped 20% to 183 million pounds. The Slough, England company, whose group first-half revenue was just under 4.7 billion pounds, put the business up for review in October.

 

Reckitt CEO Rakesh Kapoor told investors on Monday that the company had decided the pharmaceuticals unit will fare better "under a board that is focused on specialty pharmaceuticals and not on consumer healthcare that wakes up every morning thinking: how can we create value?"

 

"We are not ruling out selling this business," he said. "The preparations for a separation are to a large extent common whatever the form of the separation but we believe that a demerger is likely to be the route that adds most value."

 

"We do believe a standalone RBP will be a magnet for interesting business development opportunities," including licensing deals, he added.

 

The company began the pharma review after the Food and Drug Administration approved two generic alternatives to Suboxone. Reckitt then discontinued its Suboxone tablets and switched to a cheaper, sublingual version of the drug, which it said is proving resilient.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs